SIGi001-A-11

Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to an embryonic stem cell–like state. The cells can replicate indefinitely or, under controlled conditions, can be differentiated into any other cell type such as nerve, heart or liver cells. Medical researchers are able to use iPS cells to test how different patients might respond to new drugs or to analyse how genetic diseases develop.

The EBiSC stem cell bank is a collection of human iPS cells available to academic and commercial researchers for use in disease modelling and other forms of stem cell research. The initial collection has been generated from a wide range of donors representing specific disease backgrounds and healthy controls. EBiSC has established many routine procedures for collecting, expanding and characterizing human iPS cell lines. The stem cell bank includes iPSC cell lines derived from neurodegenerative diseases (Alzheimer′s Disease, Parkinson′s Disease, Dementia, Motor Neuron Disease (ALS) - and Huntington′s Disease), eye and heart diseases, and lines from healthy control donors for age and sex matching.

Depositor
Sigma-Aldrich

Derivation
Primary cell type: -
Reprogramming method
Vector type: Integrating
Vector: Virus
Virus type: Retrovirus
Gene list:
KLF4
MYC
POU5F1
SOX2
Have the reprogramming vectors been silenced: Yes
Merthods used: rtpcr

Xeno free conditions: no
Derived under gmp: no
Available as clinical grade: no

Characterization
Analysis of Undifferentiated Cells
Marker expression:
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
SSEA-1 No
SSEA-4 Yes
TRA 1-60 Yes
POU5F1 (OCT-4) Yes
Differentiation potency
Ectoderm:
Ectoderm
In vitro spontaneous differentiation
Marker Expressed
HES5 Yes
NeuroD1 Yes
PAX6 Yes
Endoderm:
Endoderm
In vitro spontaneous differentiation
Marker Expressed
CXCR4 Yes
GATA6 Yes
SOX17 Yes
Mesoderm:
Mesoderm
In vitro spontaneous differentiation
Marker Expressed
MIXL1 Yes
NCAM1 Yes
VIM Yes
Microbiology / Virus Screening
HIV 1: Negative
HIV 2: Negative
Hepatitis B: Negative
Hepatitis C: Negative
Mycoplasma: Negative
Sterility
Inoculation for microbiological growth: No Contaminants Detected
Mycoplasma: Not Detected
Viability: Viable post-cryopreservation

Genotyping
Karyotyping
Passage number: P37
Cell line karyotype: 46,XX[17]/47,XX,+12[2]
Karyotyping method: G-Banding

STR/Fingerprinting: A 16 allele profile has been recorded and data is available upon request, after cell line purchase.

Genetic Modification
Disease/phenotype related modifications
Disease: Corticobasal degeneration
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms
Type of modification: Isogenic
Gene: MAPT
Chromosome location: 17q21.31
Nucleotide sequence HGSV: NM_016834.4 : c.[ c.727 >T; c.[741+16C>T]+[741+16C>T]]
Target locus modification: Mutated
Description: P301S+IVS10+16 C>T; Regarding homozygosity/heterozygosity-
Disease: Progressive supranuclear palsy
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms
Type of modification: Isogenic
Gene: MAPT
Chromosome location: 17q21.31
Nucleotide sequence HGSV: NM_016834.4 : c.[ c.727 >T; c.[741+16C>T]+[741+16C>T]]
Target locus modification: Mutated
Description: P301S+IVS10+16 C>T; Regarding homozygosity/heterozygosity-

Medium: mTeSR^®
Passage method: EDTA
Matrix: Matrigel^® / Geltrex^®
CO₂ concentration: 5%
O₂ concentration: 21%
Temperature: 37°C

Note: EAUA and CLIP must be completed before order fulfillment

EBiSC is a trademark of Fraunhofer-Gesellschaft

GELTREX is a registered trademark of Life Technologies Corporation

Matrigel is a registered trademark of Corning, Inc.

mTeSR is a registered trademark of WiCell Research Institute, Inc.